Despite the promise of KRASG12C inhibitors, many patients do not experience long-term durable responses on these drugs, so it is critical to identify molecular determinants of response. Negrao, Araujo, Lamberti, Cooper, Akhave, and colleagues evaluated genomic and clinical features that impact KRASG12C inhibitor outcomes in 424 patients with non–small cell lung cancer (NSCLC) treated with either sotorasib or adagrasib and showed that coalterations in KEAP1, SMARCA4, and CDKN2A are associated with poor outcome on these inhibitors. Together, these data propose a patient stratification framework that could improve treatment selection and the tailoring of future combination therapies.

See article, p. 1556.

Small cell lung cancer (SCLC) remains the most fatal form of lung cancer. In this study, Sivakumar and colleagues present a genomic analysis of the largest cohort of SCLC tumors evaluated to date, encompassing 3,600 tumor specimens. Findings reveal rare cohorts of SCLC with potential...

You do not currently have access to this content.